{"meshTags":["ras Proteins","Receptor, Epidermal Growth Factor","Mutation","Antibodies, Monoclonal, Humanized","Proto-Oncogene Proteins","Colorectal Neoplasms","Antineoplastic Agents","Humans","Antibodies, Monoclonal","Cetuximab"],"meshMinor":["ras Proteins","Receptor, Epidermal Growth Factor","Mutation","Antibodies, Monoclonal, Humanized","Proto-Oncogene Proteins","Colorectal Neoplasms","Antineoplastic Agents","Humans","Antibodies, Monoclonal","Cetuximab"],"genes":["Anti-EGFR","anti-EGFR monoclonal antibodies","KRAS","NRAS genes"],"organisms":["6755","6755"],"publicationTypes":["Comment","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Treatment with anti-EGFR monoclonal antibodies has been successfully integrated in the continuum of care for metastatic colorectal cancer. The major challenge is the identification of patients who would benefit from treatment. Currently, the best predictor of efficacy is the absence of mutations in KRAS and NRAS genes. Clin Cancer Res; 21(24); 5415-6. Â©2015 AACR.See related article by Peeters et al., p. 5469. ","title":"Optimizing Anti-EGFR Therapy in Colorectal Cancer.","pubmedId":"26463710"}